Followers | 101 |
Posts | 13186 |
Boards Moderated | 0 |
Alias Born | 06/01/2013 |
Sunday, February 21, 2021 10:27:32 AM
https://www.merck-animal-health-usa.com/sequivity
Replication-deficient viruses
SEQUIVITY® product line (Merck; USA) can be customized to any virus
The last one has been licensed in the US as a vector for autogenous vaccine production (SEQUIVITY® product line; Merck, USA) and many such vaccines are now being used in the field.
There are several options for nanocarriers that can be used in nanovaccines including spores (bacterial), proteasomes (cell membrane based), exosomes (cellular), liposomes (lipid-based), virosomes (liposome and viral envelope protein), super fluids (biodegradable polymer), nanobeads (inert nanomaterial), VLPs (viral) and phages (viral, bacteria as targets)
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7780603/
So, since the end of April Mymetics / Baylor
Note the date here
May 27
* MERCK-BAYLOR TEAMS WILL IMPROVE MANUFACTURING PLATFORM FOR COV RBD219-N1 VACCINE CANDIDATE, WHICH WAS ORIGINALLY DEVELOPED TO TARGET SARS IN 2011-2016
* THEY WILL DEVELOP A NEW MANUFACTURING PLATFORM FOR A SECOND COVID-19 VACCINE CANDIDATE TO SHORTEN TIME TO ENTER INTO PHASE 1 CLINICAL TRIALS
* GOAL IS TO DEVELOP A SUITABLE MANUFACTURING PROCESS AND STEPS THAT WOULD LEAD TO A SCALE-UP APPROACH SUITABLE FOR PILOT AND LATER INDUSTRIAL PRODUCTION Source text for Eikon: Further company coverage:
https://www.reuters.com/article/brief-merck-kgaa-baylor-college-announce/brief-merck-kgaa-baylor-college-announce-covid-19-vaccine-collaboration-idUSFWN2D90K2
Better get um while they are still cheap, major exposure coming per Hugo himself
Ronald Kempers and the potential of a new COVID-19 nasal vaccine
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=161249382
Come on COVAX give us some more Berlin Speed Desk
Recent MYMX News
- Form 15-12G - Securities registration termination [Section 12(g)] • Edgar (US Regulatory) • 01/02/2024 06:16:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/28/2023 01:00:38 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 12/13/2023 05:15:20 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 01:53:34 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2023 08:42:46 PM
- Form SC 13E3 - Going private transaction by certain issuers • Edgar (US Regulatory) • 10/17/2023 07:08:56 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/11/2023 01:00:41 PM
FEATURED Element79 Gold Corp. Reports Significant Progress in Community Relations and Development Efforts in Chachas, Peru • Oct 9, 2024 10:30 AM
Unitronix Corp Launches Share Buyback Initiative • UTRX • Oct 9, 2024 9:10 AM
BASANITE INDUSTRIES, LLC RECEIVES U.S. PATENT FOR ITS BASAFLEX™ BASALT FIBER COMPOSITE REBAR AND METHOD OF MANUFACTURING • BASA • Oct 9, 2024 7:30 AM
BNCM COMPLETES MERGER WITH DELEX HEALTHCARE • BNCM • Oct 8, 2024 9:54 AM
CBD Life Sciences, Inc. (CBDL) Reaches Unprecedented Heights With Explosive Growth and Strategic Expansion in 2024 • CBDL • Oct 8, 2024 8:00 AM
Unitronix Corp. to Invest $3 Million in USA Unity Coin Project • UTRX • Oct 7, 2024 7:08 AM